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Abstract
Background: There is genuine need to develop interventional treatment options for management
of lung tumors. Radiofrequency ablation (RFA) is one such alternative being promoted to treat lung
tumors recently. Larger studies should help define RFA's further development. Furthermore
fluorodeoxyglucose positron emission tomography (PET) has been reported to be an accurate
indicator of treatment response in variety of tumors. This study focuses on the evaluating the
feasibility of RFA and usefulness of PET scan in lung tumors after RFA procedure.
Patients and methods: Between November 1999 and May 2002, 50 patients with primary or
metastasis pulmonary tumors underwent RFA procedure. The electrode was guided to the target
areas using computerized tomography (CT). Tumors smaller than 3.5 cm were given single RFA,
while tumors larger than 3.5 cm received RFA to multiple sites. Maximum 4 lesions or 6 target
areas were treated during one operating procedure. Whole body and/or lung PET images were
acquired; identical site CT images and chest X-ray were taken 1 week before and after RFA.
Results: Of the 50 patients, 17 had single lesions while rest had multiple lesions. Tumors smaller
than 3.5 cm were completely dissipated after RFA. In tumors larger than 3.5 cm, the part within 3.5
cm diameter dissipated. While CT showed that tumor image became larger 1 to 2 weeks after RFA
procedure. PET demonstrated tumor destruction in 70% cases, compared to 38% in CT.
Conclusion: The present study shows RFA to be safe and effective treatment option for lung
tumors. PET is superior to CT in evaluation the effectiveness of RFA treatment shortly after the
procedure.
Background
Lung cancer continues to be the leading cause of cancer
deaths in United States [1]. The overall prognosis of lung
cancer is still dismal despite all current early detection and
treatment efforts. Only about 20–25% of lung cancers can
potentially be cured by surgery. The majority of patients
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presents with locally advanced or metastatic disease, and
treatments essentially rely on external beam irradiation,
chemotherapy or a combination of both [2]. Thus other
interventional palliative treatment options have been
developed for these lesions.
Radiofrequency ablation (RFA), is an imaging-guided per-
cutaneous ablative procedure, that has been suggested to
be an effective treatment option for patients with non-
small cell lung cancer (NSCLC) and metastatic disease
who are not suitable candidates for surgery [3,4]. Guided
by computed tomography (CT), physicians are able to
localize the tumor and determine the optimal approach.
During RFA, current passing through tissue from the
active electrode leads to ion agitation and frictional heat
generation. This leads to irreparable cellular damage and
coagulation necrosis [5]. Recently a number of studies
reported its application in malignant lung tumours. Accu-
rate assessment of treatment response remains one of the
major problems.
PET has been reported to be an accurate indicator of treat-
ment response in variety of tumors [13-17]. However, its
use has been limited to evaluating disease stage in lung
tumors [18-24]. PET imaging, provides proliferation and
metabolism information, is sensitive and specific to diag-
nose malignant lesions from benign. Coleman and col-
leagues has provided substantial information in
evaluating the role of PET in management of lung cancers
[21-23]. In this report we focus on evaluating the feasibil-
ity of RFA, its complication and on evaluating the role of
PET on RFA response in lung tumors.
Patients and methods
Between November 1999 and May 2002, 50 patients with
either primary or metastatic lung tumors were enrolled in
to a prospective single group trial. Patient characteristics
are detailed in Table 1. Patients with bleeding potentials
or serious heart, liver and renal failures were excluded.
Antibiotics and medicines for prevention of bleeding were
given regularly. Every patient underwent a chest Flurode-
oxyhlucose postron emission (PET) and CT scan before
procedure.
Patients received a chest X-ray and CT for preoperative
evaluation and a repeat scan after RFA procedure. A PET
scan was performed one week after the treatment.
The Radiofrequency ablation was carried out using RF-
2000 generator and related software purchased from
Radio Therapeutics Corporation, USA; PET imaging was
done using an Advance 2 Scanner (General Electric Medi-
cal Systems, WI, USA).
Patients received general anesthesia along with local infil-
tration of Lidocaine. The electrodes were directed to target
areas during RFA procedure using CT scan. The initial
power applied was 50 W, which was subsequently
increased to a maximum 90 W over several minutes. RFA
continued for 5 to 15 min until roll off was achieved,
which continued for 2 min to stop. Tumors smaller than
3.5 cm were given full heating energy only once, while
tumors larger than 3.5 cm received multiple RFA to differ-
ent areas. Maximum 4 lesions or 6 target areas were
treated during one procedure.
One to two weeks after the procedure and a 4 hour fast,
patients were taken for PET scan. They were made to rest
for 15 min, and then received 18F-FDG 296 MBq – 440
MBq (8 mCi -12 mCi) intravenously. After another period
of rest lasting for 45–60 min, the whole body and/or lung
images was acquired by PET scanner. PET was also
acquired at 5–8 bed positions, typically from the base of
skull to the mid thigh, which was identical to the CT pro-
tocol used in the present study. The complications of the
treatment are detailed in table 2 and results are summa-
rized in table 3.
Results
After RFA procedure a number of complications were
seen. Fever and/or congested pneumonia were common-
est complications seen in 32% of patients; however, they
were cured in a week with antibiotics treatment. Pneu-
mothorax occurred during procedures in 18% and the
patients were treated with aspiration. Five of these had
small pneumothorax that did not require and treatment.
One patient had hemothorax which required intercostals
drainage (ICD) which was removed 2 days later. These
were no life threatening events or deaths.
Post procedural PET demonstrated the effectiveness of
RFA on lung tumors. Tumors smaller than 3.5 cm showed
complete response after RFA (Figure 1). In tumors larger
than 3.5 cm, the part within 3.5 cm diameter dissipated,
while the part outside this 3.5 cm area remained (Figure
2). Damage to the normal tissue outside the tumor was
not extensive in any cause.
The Chest X-ray and CT showed that tumor image became
larger 1 to 2 weeks after RFA procedure (Figure 3). These
may result from partial tissue damages, bleeding, acute
inflammation or pneumonia, and support the routing use
of antibiotics and haemostatic drugs after RFA. The tumor
destruction was picked up by PET much effectively when
compared to CT scan or chest X-ray.
Discussion
Since RFA ablates lung tumors directly and locally, mar-
ginal tissues surrounding the tumor are frequently par-World Journal of Surgical Oncology 2004, 2:30 http://www.wjso.com/content/2/1/30
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tially damaged leading to occasional pneumonia. It is
difficult for regular CT and/or chest X-rays to discriminate
pathological-physiological tissue damage and fibrillation
from the treatment effect of RFA. PET on the other hand
provides information on functional and metabolic activ-
ity anatomically, and is the only available technique
which can specifically diagnose tumors or necrosis after
surgery and radiotherapy effectively [28]. Our experience
too proves that PET is particularly superior to CT in its
ability to evaluate the effectiveness of RFA treatment early
after therapy.
RFA is a relatively noninvasive, well-tolerated approach. It
could destruct tumor completely within the effective
diameter while avoiding the surgery, side effects of radio-
therapy and toxicity of high dose chemotherapy. Our
observations suggest that RFA can kill lung tumors smaller
than 3.5 cm after a single RFA procedure. The effect of RFA
appears to be limited within 3.5 cm diameter area with
Table 1: Patient characteristics
Patients (n = 50)
Patient characteristic No %
Age, years
Median 51
Range 35–74
Sex
Male 32 64
Female 18 36
Origins
Primary lung tumors 23 46
Metastases from breast 13 26
Metastases from colon 9 18
Metastases from other places 5 10
No. of patient with lesions
Single lesion 17 34
Multiple lesions 33 66
Total lesions received RFA 120
Table 2: Complications of Radiofrequency ablation
Patients (n = 50)
Complication No %
Fever 10 20
Congested pneumonia 6 12
Pneumothorax 9 18
Hemothorax 1 2
Table 3: Early effectiveness of RFA by various techniques
Tumor destruction demonstrated
Technique No %
All 50 patients received
PET 35 70
CT 19 38
X-ray 13 26World Journal of Surgical Oncology 2004, 2:30 http://www.wjso.com/content/2/1/30
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the current instruments. However, this also suggests that
RFA may not damage the normal tissues surrounding the
small tumors. The malignant lesions dissipated in 1 to 2
weeks, while the surrounding tissue stayed intact. While at
this period regular chest CT and chest X-ray may show
enlarged lesion images. This is in agreement with other
reports. With improvements in technology, RFA in combi-
nation with other options may further reduce the morbid-
ity and mortality of cancer deaths [11]. Though
complications do occur, they are usually curable. RFA
results in a higher rate of complete necrosis and requires
fewer treatment cycles compared to traditional chemo-
PET images taken before and after RFA treatments: coronal (A, B), and Sagittal (C, D) views of PET scans of lung cancer Figure 1
PET images taken before and after RFA treatments: coronal (A, B), and Sagittal (C, D) views of PET scans of lung cancer. (A, C) 
were taken before RFA treatment; (B, D) were taken two weeks after RFA treatment.World Journal of Surgical Oncology 2004, 2:30 http://www.wjso.com/content/2/1/30
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therapy or radiotherapy. Besides CT guidance help to
localize the tumor and determine the optimal approach
further optimizes specific of targeting the tumor. For
patients with non-small cell lung malignancy who are not
candidates for surgery owing to poor cardio respiratory
reserve, RFA alone or followed by conventional radiation
therapy or chemotherapy may prove to be a treatment
option [11]. For patients with metastatic disease, RFA may
be suitable for treatment of a small tumor or reduce symp-
toms caused by large tumor burden. This technique can be
used as a primary technique or in conjunction with other
interventional procedures [11]. Further randomized con-
PET images taken before and after RFA treatments Figure 2
PET images taken before and after RFA treatments. This patient had a tumor size larger than 3.5 cm. PET scans were taken 1 
week before (A) and 2 weeks after (B) RFA treatment.
CT images taken before and after RFA treatments Figure 3
CT images taken before and after RFA treatments. The same patient PET images were shown as Figure 1. (A) was taken before 
RFA treatment, (B) was taken 2 week after RFA treatment.Publish with BioMed Central    and   every 
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trolled trials comparing RFA with conventional palliative
treatment are needed before RFA can be accepted as a rou-
tine treatment modality. Survival of patient and quality of
life issues too need be addressed.
Conclusions
Despite inherent deficiency of trial design our single
group study clearly demonstrates that RFA can be an effec-
tive treatment option for lung tumors. Unlike other inter-
ventional techniques, RFA provide controlled regions of
coagulation necrosis with a single application to an area
with 3.5 cm diameter. RFA may cure small lung tumor,
reduce tumor burden in larger lesions and may be com-
bined with external beam radiation and/or systemic
chemotherapy for further improvements. PET provides
functional and metabolic activity anatomically and is par-
ticularly superior to CT in evaluation the effectiveness
shortly after RFA procedure. Absence of follow-up infor-
mation and randomization in the current study are two
major fallacies which need to be addressed in subsequent
studies.
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